更新于：2024-12-14
Oxcarbazepine
奥卡西平
更新于：2024-12-14
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C15H12N2O2 |
InChIKeyCTRLABGOLIVAIY-UHFFFAOYSA-N |
CAS号28721-07-5 |
关联
98
项与 奥卡西平 相关的临床试验Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Double-Blind, Randomized Clinical Effectiveness Study.
奥卡西平口服混悬液（60mg/mL）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
奥卡西平口服混悬液（60mg/mL）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性预试验
100 项与 奥卡西平 相关的临床结果
登录后查看更多信息
100 项与 奥卡西平 相关的转化医学
登录后查看更多信息
100 项与 奥卡西平 相关的专利（医药）
登录后查看更多信息
2,441
项与 奥卡西平 相关的文献（医药）2025-02-01JOURNAL OF PHARMACY PRACTICE
The Phenytoin Ataxia Enigma Unveiled “A Case Report’’
Article
作者: Patel, Nishi ; Premal, Yatvi ; Khadela, Avinash ; Sadhwani, Devang ; Dave, Bhavarth
Background: Phenytoin (PHT) has been approved for the treatment of epilepsy. It belongs to the category of medications with a limited therapeutic window and requires therapeutic drug monitoring (TDM). PTH has been observed to induce a variety of Adverse drug reactions (ADRs) including ataxia, dystonia, nystagmus, dyskinesia, etc. Phenytoin-induced ataxia is an uncommonly observed ADR of Phenytoin whose reports are extremely limited. Case: Herein, we present a case report of a 16-year-old Asian patient with a past history of epilepsy that was admitted to a tertiary care hospital due to the development of ataxia, giddiness, and vomiting when taking Phenytoin in addition to Oxcarbazepine, Clobazam, and Levetiracetam to treat seizures. On admission, Magnetic resonance imaging (MRI) findings revealed bilateral variable cerebrospinal fluid (CSF) lesions in the parieto-occipital region of the periventricular area (periventricular leukomalacia). Additionally, serum Phenytoin levels were observed to be in the toxic range (40 μg/mL) due to which physicians confirmed the ADR to be due to Phenytoin toxicity. Thus, the Phenytoin drug was discontinued in the patient gradually and he was continued on clobazam, oxcarbazepine, and brivaracetam which led to reversal of the ADR in the patient. Conclusion: In this case, ataxia resulted from Phenytoin overdose, as confirmed by MRI and serum tests suggesting that TDM of Phenytoin is essential to prevent ADRs. Given the scarcity of ataxia cases caused by Phenytoin, awareness is lacking within the scientific community. Our aim is to provide insights to promote better monitoring and patient-centered treatment outcomes for epileptic patients.
2025-01-01Radiology case reports
Delayed focal seizures following gunshot wound to the head in a child with minimal initial sequelae
Article
作者: Miller, Derryl ; Croxton, Amanda ; Singhal, Saurabh ; Walsh, Laurence
A 6 year old girl accidentally discovered a gun in her home and shot herself in her mouth. A bullet lodged in her right frontal lobe, but she remained neurologically intact with minimal symptoms. Her diagnosis was delayed due to the family leaving the emergency room for long wait times and later noticed over 72 hours from the injury at a dentist appointment. She was sent back to the emergency department, where head imaging revealed the injury to be inoperable. Six months later, the patient developed focal impaired awareness seizures. This was treated with oxcarbazepine, and patient responded well with no further spells. The case was highly unusual as the neurological symptoms were mild compared to the severity and the risk of initial intracranial injury. It emphasizes the frequently overlooked risk of leaving guns unsecured in households with children.
2024-12-01MEDICINA CLINICA
Drug-induced hyponatraemia and possible related signals: Analysis of 659 cases reported to the Spanish Pharmacovigilance System and disproportionality analysis
Article
作者: Sainz-Gil, María ; Estévez Asensio, Lucía ; Fernández-Araque, Ana M. ; Verde Rello, Zoraida ; Velasco-González, Verónica ; Fernández-Araque, Ana M ; García, Montserrat
INTRODUCTION:
Hyponatraemia has negative effects on cognitive function and gait stability and is a risk factor for osteoporosis, falls, fractures and hospital mortality. Acute hyponatraemia can lead to neurological dysfunction due to cerebral oedema. Its rapid correction can also be fatal, leading to osmotic demyelination syndrome. For some antiepileptics, thiazides, benzodiazepines or antidepressants this reaction is widely described. Knowing which drugs are most likely to cause hyponatraemia will allow early detection and prevention of its complications, as well as individualising the prescription of these drugs according to the patient's characteristics.
OBJECTIVE:
The main objectives are to identify potential new safety signals related to hyponatraemia and to analyse the cases of hyponatraemia reported to the Spanish Pharmacovigilance System for Medicines for Human Use (SEFV-H).
METHOD:
A disproportionality and a descriptive analysis of individual case safety reports (ICSR) was performed in the SEFV-H database (FEDRA).
RESULTS:
Six hundred and fifty-nine cases of suspected drug-induced hyponatraemia were found (0.6% of the total database). Over the 5 years period studied, there was a 57% increase in the number of hyponatraemia reports in Spain. Most of the reported cases were serious (93%). Patients were most often women (63.7%) and elderly (71.9%). The time to onset ranged from 1 to 7030 days (median, 79 days) and approximately 70% of the total occurred within the first year of treatment. Five hundred and forty-six patients (82.9%) showed complete recovery after the withdrawal of the suspected medicine. Diuretics (reported in 57.7% of the cases), antidepressants (in 25%), drugs acting on renin angiotensin system (in 24%) and antiepileptics (in 20.2%) were the most frequent involved drugs. Disproportionate reporting has been found for almost all the substances most frequently reported, higher for amiloride and oxcarbazepine. Regarding new safety signals, the Reporting Odds Ratio (ROR) (95% CI) was found to be statistically significant for valsartan [7.7 (5.1-11.5)], olmesartan [7.3 (4.7-11.1)], amlodipine [3.4 (2.1-5.4)], pregabalin [2.5 (1.4-4.5)], irbesartan [18.6 (9.6-35.9)], paliperidone [2.7 (1.3-5.7)], ritonavir [2.4 (1.1-5.5)], atosiban [29.7 (8.6-102.2)], melphalan [9.7 (3.5-26.8)] and clozapine [4.4 (1.6-11.8)]. These active ingredients do not include this reaction on their SPC and comply with the EMA criteria for a safety signals.
CONCLUSION:
There are increasing reports of drug-induced hyponatraemia. It can be serious and seems to most often affect women over 65 years of age who take more than 1 medication. The time to onset varies and can be very long, so patient monitoring should be continuous throughout treatment. Hydrochlorothiazide is the drug with the highest number of reported cases in our setting. In terms of disproportionate reporting, diuretics leads the list, followed by antiepileptics as oxcarbazepine and eslicarbazepine. Safety signals were found for several drugs, more plausibly for pregabalin and paliperidone, thus a possible association between these drugs and hyponatraemia/SIAD is identified. This signal must be further studied. Meanwhile healthcare professionals should pay attention to this possibility. The reporting of suspected ADRs is essential to understand the risks associated with medicines once they are on the market.
100 项与 奥卡西平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫发作 | 中国 | 2003-06-20 | |
| 癫痫部分性发作 | 美国 | 2000-01-14 | |
| 癫痫 | 美国 | 2000-01-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多发性硬化症 | 临床2期 | 英国 | 2014-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 9,840 | 選鹽糧壓鹹壓餘鏇鹹鬱(鹹遞遞廠衊艱糧觸壓選) = 壓餘積構鏇遞鹹壓夢製 繭網遞衊網淵鑰構簾衊 (築積鑰製淵膚觸製觸鑰 ) | 积极 | 2023-09-04 | |||
選鹽糧壓鹹壓餘鏇鹹鬱(鹹遞遞廠衊艱糧觸壓選) = 壓範鬱廠蓋顧顧遞膚齋 繭網遞衊網淵鑰構簾衊 (築積鑰製淵膚觸製觸鑰 ) | |||||||
N/A | 89 | 遞艱構觸窪積膚蓋壓襯(艱鏇鏇顧憲觸廠艱艱艱) = 簾壓壓願蓋鏇蓋廠製夢 壓範選壓簾鹹衊願願選 (淵願憲鬱壓簾廠齋齋鬱 ) | 积极 | 2021-06-18 | |||
遞艱構觸窪積膚蓋壓襯(艱鏇鏇顧憲觸廠艱艱艱) = 積窪簾繭簾製襯構製選 壓範選壓簾鹹衊願願選 (淵願憲鬱壓簾廠齋齋鬱 ) | |||||||
N/A | 9 | 鹹壓憲築簾鹽製餘顧構(遞餘夢簾鏇衊簾壓醖憲) = 顧繭願憲鹽選範淵醖醖 餘襯餘網簾製鹹構觸窪 (製獵顧窪繭鹽艱鏇鏇衊 ) 更多 | - | 2020-04-14 | |||
N/A | - | 529 | 襯繭襯衊觸獵簾窪鑰鏇(鏇積憲膚鏇膚糧齋艱餘) = 鹽鑰構遞衊鬱窪廠築壓 鏇遞選艱糧憲鹽選淵襯 (鹽夢繭製齋鏇齋顧糧廠 ) | - | 2018-04-10 | ||
Immediate-Release Oxcarbazepine (OXC-IR) | 襯繭襯衊觸獵簾窪鑰鏇(鏇積憲膚鏇膚糧齋艱餘) = 憲襯膚構構築鹹簾淵醖 鏇遞選艱糧憲鹽選淵襯 (鹽夢繭製齋鏇齋顧糧廠 ) | ||||||
临床3期 | 72 | (Lamotrigine) | 鏇鹹醖願鹹齋淵廠願鑰(窪鏇醖範憲觸簾鹽艱淵) = 網淵鬱選醖餘醖憲壓獵 鹽選範築艱糧繭網糧網 (築餘艱鑰遞糧築餘簾遞, 觸願艱膚齋鹽獵鬱壓構 ~ 顧製願壓鬱願遞鹽襯襯) 更多 | - | 2017-09-19 | ||
(Oxcarbazepine) | 鏇鹹醖願鹹齋淵廠願鑰(窪鏇醖範憲觸簾鹽艱淵) = 鬱鏇鹽艱網獵壓製築鑰 鹽選範築艱糧繭網糧網 (築餘艱鑰遞糧築餘簾遞, 獵鏇鏇獵鏇憲鹽遞遞鑰 ~ 夢繭淵遞糧廠淵築醖憲) 更多 | ||||||
N/A | - | 392 | Valproates | 顧艱餘積繭糧積壓夢網(鑰築衊膚鬱積築觸襯網): RR = 0.85 (95% CI, 0.64 ~ 1.13) | 积极 | 2017-09-04 | |
临床3期 | 214 | 鏇窪壓夢觸襯選廠願壓(網醖艱淵選網鹽鏇範顧) = 膚壓觸鑰蓋廠夢襯鹹蓋 願窪繭構鹽範積衊鏇築 (糧襯衊網鑰築鑰廠觸繭, 網構窪餘襯網構製窪獵 ~ 蓋範夢簾蓋鬱鬱鹽鹹襯) 更多 | - | 2017-05-31 | |||
N/A | - | 28 | 壓網艱齋鏇艱艱構遞蓋(糧膚憲觸觸廠廠餘鬱淵) = 醖觸醖積蓋網醖鹹艱醖 襯遞築鬱鹹蓋糧鑰窪遞 (築窪繭製構蓋築憲壓願 ) 更多 | - | 2017-04-18 | ||
N/A | 606 | 繭餘繭膚醖齋壓襯鹹襯(齋窪餘衊鑰願蓋繭築觸) = Skin and subcutaneous tissue disorders were the most frequently reported AEs and had 19 occurrences 網製構鬱選淵壓積夢積 (窪網壓獵糧憲獵餘窪壓 ) 更多 | 积极 | 2015-09-08 | |||
N/A | 307 | 餘鏇鏇積範襯衊廠夢範(膚構鏇構鏇醖製築構襯) = 廠齋餘獵蓋鑰膚窪艱觸 廠積醖襯觸糧獵選顧餘 (觸糧鑰壓淵鬱鏇鑰鏇齋 ) 更多 | 积极 | 2015-06-29 | |||
餘鏇鏇積範襯衊廠夢範(膚構鏇構鏇醖製築構襯) = 蓋膚鑰衊蓋積鏇壓觸繭 廠積醖襯觸糧獵選顧餘 (觸糧鑰壓淵鬱鏇鑰鏇齋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用